HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FCC To ‘Clarify’ Section 230; FDA On Scented Sanitizers; A Mixed Holiday Shopping Forecast; News In Brief

Executive Summary

The Federal Communications Commission intends to “clarify” Section 230 of the Communications Decency Act, suggesting “an overly broad interpretation that in some cases shields social media companies from consumer protection laws” in unintended ways. More news in brief.

You may also be interested in...

Consumers Cool On Holiday Spending With Doubts ‘Deep Discounts’ Are Coming

One likely reason for tighter spending plans is consumers aren’t expecting “deep discounts” offered in US earlier in 19 pandemic, shows Simon-Kucher survey. Four times as many than in 2021 expect 10% or less discounts.

Amazon Can Be Liable For Prop 65 Warning Failures, California Appeals Court Says

Even when it comes to foreign-manufactured cosmetics containing undeclared ingredients listed under California’s Prop 65, online marketplaces the likes of Amazon can be responsible for providing exposure warnings to consumers, according to California’s First Appellate District.

Falling At The Start Line: Chinese Firms Face Multiple Commercial Challenges Beyond Price, Coverage

Sales of a global first-in-class dermatology drug that gained its first approval in China are falling well behind those of its overseas counterpart. In this case study, Scrip takes a deep dive into the multiple underlying factors determining success in the world's second-largest pharma market beyond pricing and reimbursement coverage, including complex hospital entry, dual channels and competition considerations. 


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts